MAM
REGN icon

Mainsail Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mainsail Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$234K Buy
+317
New +$240K 0.09% 128
2026
Q2 		– Sell
-277
Closed -$214K – 207
2026
Q1 		$214K Sell
277
-8
-3% -$6.13K 0.1% 101
2025
Q4 		$220K Buy
+285
New +$194K 0.09% 87

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Mainsail Asset Management's REGN Position: Q3 2026 in Review

Mainsail Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 317 shares worth $234K. The stake represents 0.09% of the portfolio and ranks #128 among its holdings. This is a return to the name: Mainsail Asset Management previously reported a position in REGN as recently as Q1 2026.

Mainsail Asset Management first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 175 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Mainsail Asset Management held 317 shares of Regeneron Pharmaceuticals worth $234K as of Q3 2026.
  • Regeneron Pharmaceuticals was a new Mainsail Asset Management position in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.09% of Mainsail Asset Management's portfolio in Q3 2026, its #128 holding.
  • Mainsail Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 175 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Mainsail Asset Management's 13F filing for Q3 2026, filed 14 Oct 2026.